[Featured Stock] Kumho HT Highlights CDMO Agreement with Samsung Biologics for COVID-19 Therapeutic Antibodies Increase

[Asia Economy Reporter Jang Hyowon] Kumho HT is showing strength. Amid the resurgence of the COVID-19 Delta variant, the CDMO agreement between Dinona, which is scheduled to merge, and Samsung Biologics is being highlighted.

As of 1:37 PM on the 8th, Kumho HT is trading at 2,525 KRW, up 3.91%.

Previously, Dinona signed a CDMO agreement with Samsung Biologics for the new COVID-19 antibody treatment substance ‘DNP-019’.

Additionally, Dinona has obtained export approval for its COVID-19 antibody rapid diagnostic kit (RDT) from the Ministry of Food and Drug Safety and has applied for emergency use authorization in major countries including the U.S. Food and Drug Administration (FDA).

Kumho HT plans to hold a shareholders' meeting on September 17 to seek approval for the merger with ‘Dinona’.

This content was produced with the assistance of AI translation services.